Department of Orthopedics Ward 3 The General Hospital of Ningxia Medical University, Yinchuan Ningxia, China.
Medical Experiment Center, General Hospital of Ningxia Medical University, Ningxia, China.
Acta Pharm. 2024 Mar 30;74(1):101-115. doi: 10.2478/acph-2024-0003. Print 2024 Mar 1.
Deguelin exhibits antiproliferative activity against various cancer cell types. Previous studies have reported that deguelin exhibits pro-apoptotic activity against human cancer cells. The current study aimed at further elaborating the anticancer effects of deguelin against multiple myeloma cells. Cell growth estimations were made through MTT assay. Phase contrast microscopy was used for the analysis of the viability of multiple myeloma cells. Colony formation from multiple myeloma cells was studied using a clonogenic assay. Antioxidative assays for determining levels of glutathione (GSH) and superoxide dismutase (SOD) were carried out after treating multiple myeloma cells with deguelin. The apoptosis of multiple myeloma cells was studied using AO/EB and Annexin V-FITC/PI staining methods. Multiple myeloma cell cycle analysis was performed through flow cytometry. mRNA expression levels were depicted using qRT-PCR. Migration and invasion of multiple myeloma cells were determined with the wound-healing and transwell assays, respectively. Deguelin specifically inhibited the multiple myeloma cell growth while the normal plasma cells were minimally affected. Multiple myeloma cells when treated with deguelin exhibited remarkably lower viability and colony-forming ability. Multiple myeloma cells treated with deguelin produced more SOD and had higher GSH levels. The multiple myeloma cell growth, migration, and invasion were significantly declined by administration of deguelin. In conclusion, deguelin treatment, when applied induced apoptotic cell death and resulted in mitotic cessation at the G2/M phase through modulation of cell cycle regulatory mRNAs in multiple myeloma cells.
德古拉因表现出抗多种癌细胞的增殖活性而被关注。之前的研究报告表明，德古拉因对人类癌细胞表现出促凋亡活性。本研究旨在进一步阐述德古拉因对多发性骨髓瘤细胞的抗癌作用。通过 MTT 法进行细胞生长估计。使用相差显微镜分析多发性骨髓瘤细胞的活力。通过集落形成测定研究多发性骨髓瘤细胞的克隆形成。在用德古拉因处理多发性骨髓瘤细胞后，进行抗氧化测定以确定谷胱甘肽 (GSH) 和超氧化物歧化酶 (SOD) 的水平。通过 AO/EB 和 Annexin V-FITC/PI 染色方法研究多发性骨髓瘤细胞的凋亡。通过流式细胞术进行多发性骨髓瘤细胞周期分析。使用 qRT-PCR 描绘 mRNA 表达水平。通过划痕愈合和 Transwell 测定分别确定多发性骨髓瘤细胞的迁移和侵袭。德古拉因特异性抑制多发性骨髓瘤细胞生长，而正常浆细胞则受到最小影响。用德古拉因处理的多发性骨髓瘤细胞表现出明显较低的活力和集落形成能力。用德古拉因处理的多发性骨髓瘤细胞产生更多的 SOD，并且具有更高的 GSH 水平。通过给予德古拉因，多发性骨髓瘤细胞的生长、迁移和侵袭明显下降。总之，德古拉因治疗通过调节多发性骨髓瘤细胞周期调节 mRNA，诱导细胞凋亡并导致有丝分裂停滞在 G2/M 期，从而导致细胞死亡。
